News

Moby summary of Pfizer Inc.'s Q2 2026 earnings call

The quarter exposed where Pfizer's recovery is really coming from

Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported...

Pfizer faces $17 billion patent cliff as investors brace for earnings

Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here’s what to expect.

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

There is more to this stock than meets the eye.

Bristol Myers Squibb faces declining revenue in its legacy drug portfolio, but new products like Opdivo are offsetting the drop.

OPKO Health Inc (OPK) reports significant revenue growth in pharmaceuticals and a notable reduction in net loss, despite challenges in diagnostics.

Pfizer is set to announce its second-quarter earnings next month, and Wall Street expects a double-digit decline in its profit.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

(Bloomberg) -- Turns out, loading up on technology giants isn’t the only route to better returns. Value companies, too, stand a decent chance of trouncing the market — as long as several conditions are met. Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Threatens Iran With ‘Bi

Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous

Novavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par

Moby summary of Pfizer Inc.'s Q1 2026 earnings call

BioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m

Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

US equity futures were trending higher on Tuesday as traders await a fresh batch of corporate earnin

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.

Pfizer Inc. will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the pharmaceutical company to report quarterly earnings of 72 cents per share. That’s down from 92 cents per share in the year-ago period. Benzinga Pro puts the consensus estimate for Pfizer's quarterly revenue at $13.8 billion. Pfizer reported $13.71 billion last year. With the recent buzz around the company, some investors are eyeing potential gains from its dividends. Currently,